Catalent Announces Closing Of Secondary Public Offering Of Common Stock

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the closing of a previously announced registered underwritten secondary public offering of its common stock by certain of its stockholders (the “Selling Stockholders”). The Selling Stockholders sold a total of 10 million shares of Catalent’s common stock at a price to the public of $24.85 per share. Catalent did not sell any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders.

Goldman, Sachs & Co acted as underwriter for the offering.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of such shares of common stock in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering of the shares of common stock was made pursuant to an effective shelf registration statement. The offering was made only by means of a prospectus, copies of which may be obtained from Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (212) 902-1171, facsimile: (212) 902-9316, e-mail: prospectus-ny@ny.email.gs.com. The registration statement is available on the SEC’s website at www.sec.gov under the registrant’s name.